Simcere Pharmaceutical Group
The 10-second takeaway
For the quarter ended March 31 (Q1), Simcere Pharmaceutical Group missed estimates on revenues and met expectations on earnings per share.
Compared with the prior-year quarter, revenue grew and GAAP earnings per share didn't change.
Gross margins shrank, operating margins improved, net margins grew.
Simcere Pharmaceutical Group recorded revenue of $77.3 million. The three analysts polled by S&P Capital IQ predicted sales of $82.3 million on the same basis. GAAP reported sales were 5.1% higher than the prior-year quarter's $73.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.08. The one earnings estimate compiled by S&P Capital IQ averaged $0.08 per share. GAAP EPS of $0.08 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 82.0%, 190 basis points worse than the prior-year quarter. Operating margin was 8.9%, 280 basis points better than the prior-year quarter. Net margin was 5.9%, 10 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $88.5 million. On the bottom line, the average EPS estimate is $0.13.
Next year's average estimate for revenue is $343.5 million. The average EPS estimate is $0.38.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 232 members out of 243 rating the stock outperform, and 11 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Simcere Pharmaceutical Group a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Simcere Pharmaceutical Group is hold, with an average price target of $9.08.
Over the decades, small-cap stocks like Simcere Pharmaceutical Group have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.
- Add Simcere Pharmaceutical Group to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings. He is the co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.